Home › Cerebral Palsy › NCT05018871

Safety of Cultured Umbilical or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP

Safety of Cultured Umbilical or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Cerebral Palsy

Who can join

All ages · All sexes

Inclusion Criteria:

* Diagnosis of Cerebral Palsy

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant Abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety
* Previous organ transplant
* Seizure disorder
* Hypersensitivity to sulfur

About the study

This trial will study the safety and efficacy of intravenous infusion of cultured umbilical or placental derived mesenchymal stem cells for the treatment of Cerebral Palsy

What is being tested

• Umbilical or placental derived mesenchymal stem cells (biological)

Sponsor: The Foundation for Orthopaedics and Regenerative Medicine · Participants: 15 · Started: 2026-12

Contact the study team

• Chadwick Prodromos, MD · Phone: 847-699-6810

Official record on ClinicalTrials.gov — NCT05018871

Locations in the U.S.

Conditions

• Cerebral Palsy

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.